Generics - Antibiotics and Infectious diseases

Filter

Popular Filters

64 to 88 of 1442 results

PhRMA slams US President’s claims that Budget invests in innovation

06-03-2014

Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive John Castellani…

GenericsNorth AmericaPatentsPharmaceuticalPoliticsResearchUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA

04-03-2014

Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

AbbVie presents positive Phase III results in patients with chronic hepatitis C

AbbVie presents positive Phase III results in patients with chronic hepatitis C

04-03-2014

The first detailed results from US drugmaker AbbVie’s pivotal Phase III study, PEARL-III, have been…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

Natco prevails in Indian Copaxone patent dispute with Teva

Natco prevails in Indian Copaxone patent dispute with Teva

03-03-2014

Hyderabad, India-based Natco Pharma has won a significant patent battle against Israeli generics giant…

Asia-PacificCopaxoneGenericsIndiaNatco PharmaPatents & Trade marksTeva Pharmaceutical Industries

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Roche collaborates with Discuva to combat life-threatening infections

28-02-2014

Swiss pharma major Roche and privately-held UK biotech firm Discuva have entered into a worldwide collaboration…

Antibiotics and Infectious diseasesDiscuvaLicensingPharmaceuticalResearchRoche

Valeant Pharma returns to profit, boosted by B&L acquisition

27-02-2014

Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Mylan 4th-qtr 2013 adjusted diluted EPS increases 20%, beating expectations

27-02-2014

US generics major Mylan reported financial results for the fourth-quarter and full year 2013, showing…

FinancialGenericsMylan Laboratories

BIO urges Indiana Governor to sign Bill on interchangeable biologic medicines

27-02-2014

US trade group the Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF)…

BiosimilarsGenericsLegalNorth AmericaRegulationUSA

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Positive top-line results for Pfizer’s Prevenar 13 in pneumonia in over 65s

25-02-2014

US pharma behemoth Pfizer says that top-line results from a study of Prevenar 13 (pneumococcal 13-valent…

Antibiotics and Infectious diseasesPfizerPharmaceuticalPrevenarResearchVaccines

Valneva initiates fourth antibody discovery program for Sanofi Pasteur

25-02-2014

European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

FDA proposed rule to change label requirements would cause dangerous confusion, raise costs

24-02-2014

The Food and Drug Administration’s Proposed Rule to change prescription drug label requirements risks…

GenericsNorth AmericaRegulationUSA

MSF warns of impact of proposed EU trade mark infringement measures

24-02-2014

Ahead of a vote tomorrow in the European Parliament on proposed strengthened EU enforcement of European…

EuropeGenericsPatents & Trade marks

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

US GPhA member support for GDUFA promise and progress

US GPhA member support for GDUFA promise and progress

21-02-2014

The US Food and Drug Administration’ Office of Generic Drugs acting director Kathleen Uhl, highlighted…

GenericsNorth AmericaRegulationUSA

Setting the record straight: Australia’s PBS expenditure is in decline

21-02-2014

Comments made this week by Australia’s federal Health Minister, Peter Dutton MP, about expenditure…

Asia-PacificAustraliaFinancialGenericsHealthcarePharmaceutical

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

20-02-2014

Acquisitive Ireland-headquartered generics major Actavis says that net revenue leapt 59% to $2.779 billion…

ActavisFinancialGenerics

FDA accepts The Medicines Company's NDA for oritavancin with priority review

FDA accepts The Medicines Company's NDA for oritavancin with priority review

19-02-2014

The US Food and Drug Administration has accepted the filing of The Medicines Company’s New Drug Application…

Antibiotics and Infectious diseasesNorth AmericaoritavancinPharmaceuticalRegulationThe Medicines CompanyUSA

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Infectex acquires exclusive rights to Qurient's TB drug Q203

13-02-2014

Russian and Korean biotech companies Infectex and Qurient have entered a license agreement granting Infectex…

Antibiotics and Infectious diseasesEastern EuropeInfectexLicensingPharmaceuticalQ203QurientRussia

64 to 88 of 1442 results

Back to top